Physician profile
Jean-Marc Alling
NPI 1366641680
$2,757.23
in general payments reported to CMS, 2019-2025
12 companies · $827 in 2025
The $827 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2021: $240 · 2022: $301 · 2023: $492 · 2024: $516 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $537.24 | 2019-2025 | Acuvue |
| Oyster Point Pharma, INC. | $463.84 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $326.90 | 2023-2025 | Xiidra, Miebo, Infuse |
| Coopervision INC. | $284.40 | 2019-2025 | Misight Contact Lens |
| Allergan, INC. | $256.36 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $250.00 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $241.10 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $161.52 | 2022-2024 | Total30 |
| Glaukos Corporation | $110.30 | 2025 | Photrexa Viscous and Photrexa |
| Abb Con-Cise Optical Group LLC | $77.21 | 2021-2025 | Contact Lens, Spectacle Lenses |
| Horizon Therapeutics Plc | $24.22 | 2023 | Tepezza |
| Lombart Brothers, INC. | $24.14 | 2023 | Opd-III |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean-Marc Alling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.